Genetic causes and mechanisms of distal renal tubular acidosis

Daniel Batlle and Syed K. Haque

Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Correspondence and offprint requests to: Daniel Batlle; E-mail: d-batlle@northwestern.edu

Abstract

The primary or hereditary forms of distal renal tubular acidosis (dRTA) have received increased attention because of advances in the understanding of the molecular mechanism, whereby mutations in the main proteins involved in acid–base transport result in impaired acid excretion. Dysfunction of intercalated cells in the collecting tubules accounts for all the known genetic causes of dRTA. These cells secrete protons into the tubular lumen through H+-ATPases functionally coupled to the basolateral anion exchanger 1 (AE1). The substrate for both transporters is provided by the catalytic activity of the cytosolic carbonic anhydrase II (CA II), an enzyme which is also present in the proximal tubular cells and osteoclasts. Mutations in ATP6V1B1, encoding the B-subtype unit of the apical H(+) ATPase, and ATP6V0A4, encoding the a-subtype unit, lead to the loss of function of the apical H(+) ATPase and are usually responsible for patients with autosomal recessive dRTA often associated with early or late sensorineural deafness. Mutations in the gene encoding the cytosolic CA II are associated with the autosomal recessive syndrome of osteopetrosis, mixed distal and proximal RTA and cerebral calcification. Mutations in the AE1, the gene that encodes the Cl−/HCO3− exchanger, usually present as dominant dRTA, but a recessive pattern has been recently described. Several studies have shown trafficking defects in the mutant protein rather than the lack of function as the major mechanism underlying the pathogenesis of dRTA from AE1 mutations.
Keywords: acidosis; AE1; carbonic anhydrase; distal RTA; H⁺-ATPase

Introduction

The renal tubular acidosis (RTA) syndromes encompass a disparate group of tubular transport defects that have in common the inability to secrete hydrogen ions (H⁺), a defect that is disproportionately large in relation to any reduction in the glomerular filtration rate (GFR) [1–3]. This inability results in failure to excrete acid in the form of ammonium (NH₄⁺) ion and titratable acids or to reabsorb some of the filtered bicarbonate (HCO₃⁻) load. In either situation, there is a fall in plasma bicarbonate leading to chronic metabolic acidosis. Much of the morbidity in the RTA syndromes is attributable to the systemic consequences of chronic metabolic acidosis namely growth retardation, bone disease and kidney stones [2–4].

The initial classification of tubular defects in urinary acidification was designed to separate those involving the distal nephron from those affecting the proximal nephron [4]. Clinical and functional studies allow classification into four types, historically numbered in the order of discovery: proximal (Type 2), classic distal (Type 1), hyperkalemic distal (Type 4) and combined proximal and distal (Type 3). dRTA was the first RTA recognized, and thus, the terms ‘Type 1’ or ‘classic RTA’ have been used to describe this form of RTA. dRTA is characterized by an inability to lower urine pH despite severe acidemia and minimal HCO₃⁻ wastage. Proximal RTA (Type 2), by contrast, is characterized by marked HCO₃⁻ wastage, but preserved ability to lower urine pH when plasma HCO₃⁻ (and therefore filtered HCO₃⁻) is below a certain level. The term ‘Type 3 RTA’ is used to describe patients, in whom HCO₃⁻ wastage coexists with failure to lower urine pH despite profound acidemia, thus demonstrating a mixed pattern of tubular dysfunction [4].

Patients with RTA are often growth retarded because of the chronic metabolic acidosis unless alkaline therapy is initiated earlier in life. Associated features are nephrocalcinosis, nephrolithiasis, hypercalciuria and hypocalciuria. Polyuria is often encountered, and may be related, at least in part, to the associated hypokalemia [5]. Other extrarenal manifestations depend on the gene mutated and the type of mutation [6–8]. Hemolytic anemia may be seen in some types of hereditary RTA associated with AE1 mutations, whereas deafness is an important feature in some H⁺-ATPase mutations.

Hypokalemia is a striking feature of dRTA or Type 1 RTA, but it is also frequently seen with proximal RTA or Type 2 RTA [9]. Hyperkalemic forms of distal RTA, however, were later recognized. The first type described was attributable to aldosterone deficiency, and the term Type 4 RTA was coined to describe it [10]. In addition, hyperkalemic distal renal tubular acidosis (dRTA) due to a combined tubular defect in hydrogen (H⁺) and potassium (K⁺) ion secretion possibly resulting from a voltage-dependent defect was also described in the early 1980s [11–13]. In this review, we will limit the discussion to the non-hyperkalemic types of RTA and focus only on hereditary distal RTA. Many of the acquired causes of RTA, particularly the distal form, are due to the immune mechanism or drug-induced kidney damage and will not be discussed here. The purpose of this review is to provide an update on recent studies on hereditary distal RTA and particularly the mechanisms involved in the causation of distal RTA at the molecular level.

Causes of hereditary dRTA

Acid-base transport within the distal nephron is primarily effected by specific transporters located in intercalated cells [8, 14–17]. Distal RTA can be attributed to failure of the kidney-intercalated cells to acidify the urine normally as a result of dysfunction in any of the transporters involved in the overall process of acidifying the urine maximally (Figure 1). As a result of decreased distal H⁺-ion secretion, there is a failure to lower urine pH maximally and excrete acid as ammonium and other titrable buffers which with time results in the development of hyperchloremic metabolic acidosis, the hallmark of classic or Type 1 dRTA. The incomplete form of distal RTA, like complete dRTA, presents with failure to maximally lower urine pH, but blood pH and plasma bicarbonate are normal [2]. Acid load with ammonium chloride reveals the defect by showing that urine pH could not be maximally lowered, and remains above 5.3.

The currently known mutations resulting in inherited dRTA have been identified in transporters present in intercalated cells such as the anion exchanger 1 (AE1), the B₁ and a₄ subunits of H⁺-ATPase and the cytosolic carbonic anhydrase II (CA II) [18–37]. It should be noted, however, that the rate of H⁺-ion secretion by α-intercalated cells is importantly influenced by the rate of Na⁺ transport in the neighboring principal cells that are involved in Na⁺ reabsorption and K⁺ secretion, but not in H⁺ secretion [9].

The various mutations in the acid–base transporters involved in the causation of dRTA involve complex mechanisms that are specific for each transporter and some of the specific mutations involved. It has been long recognized that cytosolic CA, by catalyzing the hydration of CO₂ to H⁺ and HCO₃⁻, plays a key role in the intracellular generation of these ions from CO₂ that enters the tubular cells (Figure 1). In fact, the first type of hereditary distal RTA described was that caused by CA deficiency [38]. A key requirement for proper acidification of the urine by the α-intercalated cells is that the secretion of protons in the apical membrane (largely a function of the H⁺-ATPase) be coupled to extrusion of bicarbonate in the basolateral membrane, a process carried out by the AE1 exchanger (Figure 1).

Failure of H⁺-ATPase-driven H⁺-ion secretion has been the main mechanism long postulated to account for the inability to lower urine pH maximally in patients with dRTA [1, 39]. The importance of the exit step for bicarbonate for optimal distal acidification of the urine, however, is also evident from physiologic studies and confirmed by the clinical phenotype of dRTA seen in
patients with mutations in the AE1 exchanger as discussed in detail below.

**AE1 mutations**

The AE1 gene belongs to the SLC4 family of genes and is present on chromosome 17 q21-22 [8, 14]. AE1 proteins encoded by this gene are expressed on the erythrocyte plasma membrane and the basolateral membrane of the kidney α-intercalated cells in the connecting tubules, the cortical collecting duct and also medullary collecting duct [15, 16]. AE1 proteins bring about an exchange of intracellular bicarbonate ($\text{HCO}_3^-$) for extracellular chloride ($\text{Cl}^-$) ions [14]. In the α-intercalated cells, this exchanger provides the exit step for bicarbonate (Figure 1A). This exchanger is distinct from other chloride–bicarbonate exchanger in the kidney, such as the pendrin, which is located in the apical membrane of β-intercalated cells (Figure 1B) and non-A-, non-B-intercalated cells [17].

AE1 mutations causing dRTA were initially described by Bruce et al. [18], and later by Karet et al. [19]. Some AE1 mutations are associated with hemolytic diseases such as hereditary spherocytosis (HS) without any evidence of dRTA [6]. Others cause dRTA but without hemolytic disease or only mild asymptomatic red cell fragility [6]. In very rare instances, mostly from Southeast Asia, dRTA and hemolytic disease have been reported to occur together [6, 20, 22]. In the following sections, we discuss AE1 mutations grouped as those associated with autosomal dominant (AD) and those associated with recessive RTA.

The AD AE1 mutations were first described in several affected families from Southeast England [18]. Missense mutations in codon Arg589 of the AE1 gene, resulting in substitution of arginine by histidine (R589H) or cysteine (R589C), and in codon Ser613, resulting in substitution of serine by phenylalanine, were identified [18]. No mutations were found in the unaffected members of the families [18]. A subsequent study revealed new AD
mutations: R901X and R589S [19]. Mutation R901X was found to cause premature termination of protein at codon position 901 leading to a truncated AE1 protein by 11 amino acids, whereas R589S was a missense mutation in codon Arg589 which caused substitution of arginine by serine [19]. In these early studies, AE1 mutations were not found in any of the families with autosomal recessive dRTA [19]. This led to the initial belief that AE1 mutations always cause AD dRTA. However, mutations in association with recessive dRTA were later identified as discussed below [6, 21].

Dominant AE1 mutation cases can present as complete or incomplete dRTA [18, 23]. Bruce et al. [18] reported incomplete dRTA in 8 of 18 patients investigated and, interestingly, over the course of 10 years, two of the eight went on to develop acidosis. Incomplete dRTA was also found in the father of two affected children from Brazil [23]. AD A888L mutation was later identified in this family.

AD cases are usually diagnosed at a later age than recessive ones [2, 5]. Karet et al. [19] reported some cases of AD dRTA at 10 years of age or later. However, Bruce et al. [18] reported four patients diagnosed below 10 years of age and one was diagnosed as early as 2 years. In Bruce et al.’s study, most patients, at the time of diagnosis, had plasma bicarbonate near the lower normal range. Plasma potassium ranged from 3.0 to 4.2 mmol/L with most being in the normal range. In general, patients with AE1 mutations seem to have less severe hypokalemia than those with recessive dRTA due to H+-ATPase mutations [9]. Maximal urine osmolality was below normal, and eight with recessive dRTA due to H+-ATPase mutations [9].

Recently, the only case in a Caucasian family was reported from Scandinavia [30]. In contrast to AD dRTA, autosomal recessive patients always present as complete dRTA. In the first reported case (G701D/G701D mutation), the male patient (age = 3.5 years) presented with lethargy, anorexia and delayed growth [21]. Biochemical analysis showed hypokalemia, hyperchloremic acidosis, an alkaline urinary pH, bilateral nephrocalcinosis, rachitic bone changes and hemolytic anemia. Their parents and other unaffected siblings were normal, and incomplete dRTA was not identified in them [21]. Choo et al. [31] reported a Q759H mutation in two children from Malaysia.

Most autosomal recessive AE1 mutations reported so far have been seen associated with hemolytic anemia as a result of Southeast Asia ovalocytosis [21] or HS [28]. Hemolytic anemia, however, is not always present in autosomal recessive AE1 mutations. A dRTA patient from northeast Thailand was reported with rickets and bilateral nephrocalcinosis without anemia [22]. A compound heterozygous recessive mutation (S773P/G701D) was identified in this patient [22].

Mechanisms of dRTA in AE1 mutants

The molecular mechanisms that render a mutated protein dysfunctional are complex and may involve an array of defects spanning from internal sequestration of a given transporter to its mistargeting to the plasma membrane. A scheme of AE1 mutations resulting in non-function, internal sequestration in endoplasmic reticulum or Golgi apparatus, or mistargeting to the apical membrane is shown in Figure 2. Next are reviewed studies that have shown various mutations in patients with dRTA and cell biology studies aimed at exploring the potential mechanism that result in impaired function of the various acid–base transporters involved.

Initial studies used chloride transport in Xenopus oocytes as a way to study AE1 exchange activity in vitro [18]. Expression of erythroid and kidney mutant protein (R589C, S613F and R589H) revealed normal chloride transport activity with all mutant proteins except R589H mutant which had reduced chloride activity in erythrocytes [18]. Mutant proteins were also found to be expressed on erythrocytes and oocyte cell membranes [18, 24]. This suggested that these proteins might traffic normally to the surface of the α-intercalated cells of human kidney. Later studies with the R589H mutation expressed on human embryonic kidney cells, however, showed a severe trafficking defect of the kidney kAE1 but not of erythrocyte anion exchanger [32]. A schematic overview of mechanisms leading to AE1 dysfunction at the cellular level is summarized in Figure 2. The mutated protein appears to be sequestered in the endoplasmic reticulum, and although functional, it does not traffic to the basolateral membrane and therefore bicarbonate cannot exit the cell (Figure 2B) [32]. Recessive kAE1 G701D and S773P mutants, unlike dominant R589H mutants, traffic to the basolateral membrane when co-expressed with kAE1 wild-type (WT) [33]. This has been suggested
as an explanation for the absence of dRTA in heterozygous recessive patients.

Glycophorin A has been studied for its role in increasing surface expression of AE1 mutant proteins [29]. Studies on Xenopus oocytes showed increased surface expression of autosomal recessive G701D resulting in 100% return of transport activity to normal [20]. AD A858D and autosomal recessive ΔV850 mutant AE1 showed lesser increase in surface expression and resulted in only 64 ± 5% and 43 ± 3% return of chloride transport activity, respectively [20]. A similar glycophorin rescue pattern was observed with the recessive mutation S667P [29]. Glycophorin A is present in red blood cells but absent from kidney cells [34]. It has, therefore, been suggested that this could be the reason why kAE1 mutation rarely leads to a red blood cell defect [34].

The underlying defect caused by AE1 mutation leading to dRTA has also been studied on Madin-Darby Canine Kidney (MDCK) cells [33]. Studies on mutations known to cause dRTA have revealed several mechanisms that could lead to reduced chloride–bicarbonate exchange and thus lead to dRTA [33]. This has been the subject of recent excellent reviews [5, 6]. Polarized MDCK cells as opposed to non-polarized MDCK have been shown to be

Fig. 2. Schematic model of various mechanisms, whereby kAE1 mutations result in abnormal Cl^-/HCO_3^- in dRTA. (A) Normal, (B) internal sequestration in the endoplasmic reticulum (R589H, S613F, S667P) [29, 32, 33], (C) internal sequestration in the golgi apparatus (G701D) [33], (D) non-functional/partially functional (S773P) [22], (E) mistargeting to both the apical membrane and basolateral (G609R, R901X, M909T) [35–37].
more representative of the α-intercalated cells in the kidney [35]. While AE1 expression is diffuse in non-polarized MDCK cells, it is expressed exclusively in the basolateral membrane of polarized MDCK cells, a finding that is similar to α-intercalated cells in the kidney [35].

Using this cell model, Cordat et al. [33] studied two dominant (R589H and S613F) and two recessive (S773P and G701D) AE1 mutations in MDCK cells. In polarized MDCK cells, they found that dominant R589H and S613F mutants were retained in the endoplasmic reticulum (Figure 2B). Two hours later, these mutant proteins were barely detectable suggesting rapid degradation [33]. In some cells, mutant protein was mistargeted to the apical membrane [33].

Recessive mutant protein was sequestered in the Golgi apparatus (G701D; Figure 2C) or trafficked to the basolateral membrane to a lesser extent than the KAE1 WT (S773P; Figure 2D) [33]. A previous MDCK study with recessive S667P mutation has shown sequestration in the endoplasmic reticulum [29]. Misfolding leading to impaired function and decreased half-life has been described with S773P-recessive mutant proteins causing dRTA [22].

An AE1 mutation (M909T) that affects the C-terminal of AE1, found in a family with dominant dRTA, was recently demonstrated in polarized MDCK cells to be localized both in the apical and basolateral membrane [37]. This pattern of abnormal mistargeting is illustrated in Figure 2E. It was also elucidated for the first time that the kidney AE1 wild-type traffics directly to the basolateral membrane without any transient traffic to the apical membrane and then retrieval to the basolateral membrane as with other proteins [37].

Another study on another dominant mutation (G609R) found mistargeting to both the apical membrane and the basolateral membrane in polarized MDCK cells [36]. The same mutant proteins have been shown to retain normal chloride/bicarbonate exchange function in erythrocytes and Xenopus oocytes [18, 24]. Mistargeting to the apical membrane would cause bicarbonate secretion and thus a highly alkaline urine, and this was suggested in a patient with G609R mutation [36] (Figure 2E). Mistargeting to the apical membrane alone has been reported in R901X mutants in stably transfected cells [35].

Recent studies have documented reasonably well the interconversion of α-intercalated cells and β-intercalated cells [40, 41]. Exposure to acid in the basolateral medium identified a significant conversion of β-intercalated cells to α-intercalated cells [40]. This conversion was attributed to the deposition of hensin in the extracellular matrix. This has been studied in hensin knock-out mice that develop acidosis and have only β-intercalated cells expressing pendrin, the apical Cl⁻–HCO₃⁻ exchanger [42]. In another study, bicarbonate (HCO₃⁻) exposure initiated the conversion of β-intercalated cells to α-intercalated cells [41]. Whether this conversion depends on hensin degradation remains to be shown. Hensin mutation as one of the possibilities of hereditary dRTA in humans should be considered, but remains to be documented [42].

CA II gene mutations

The CA II gene is located at q22 on chromosome 8 [2]. CAs are zinc metalloenzymes that catalyze the reversible hydration of CO₂ to form HCO₃⁻ and H⁺ [43]. There are 15 known CAs. CA II is the most widespread and has the highest catalytic activity [44].

CA II, CA IV and CA XII are expressed by the human kidney [45]. A total of 95% of renal CA consists of cytoplasmic CA II, and the rest are membrane-associated CA IV and CA XII [46]. In the kidney, CA II is present in the proximal tubule, thin descending limb, thick ascending limb and intercalated cells of the cortical collecting duct, outer medullary collecting duct and inner medullary collecting duct (IMCD) [46].

Twenty-three different mutations causing RTA were identified in several families [6]. These had an autosomal recessive inheritance pattern [38]. Mutations in CA II lead to CA II deficiency, which is measurable in circulating erythrocytes [38, 47]. CA II deficiency has been reported in several ethnic backgrounds, including Arabic, Italian, German, French, Hispanic and African American [2, 38]. Later novel mutations were identified in other ethnic groups, which included an Irish family, a Turkish family of non-Arabic descent, an Asian Indian and British origin family [48]. Consanguinity is a common feature in families with CA II mutations [2, 48].

CA II deficiency is particularly common in the Middle East [49]. More than 70% of the cases have been described from the Arabian Peninsula [49, 50]. Patients of Arabic origin have a unique splice junction mutation at the junction of exon 2–intron 2 of the CA II gene (c.232+1 G > A) [51]. A study done in patients from Tunisia and Algeria traced the ancestry of all affected patients studied to an old Arab tribe of Helal that had settled there in the 10th century. Clinically, Arabic patients have a very severe phenotype. Unlike American and Belgian patients (H107Y mutations), severe cognitive impairment is a consistent feature [50]. This was suggested to be because missense mutations are phenotypically less severe than splice site mutations, and frameshift mutations [48, 49]. However, later studies found a frameshift mutation in an American patient with only mild learning disabilities [48].

The lack of cognitive impairment has been reported from several patients with missense mutations. Shah et al. [48] reported two affected male children in a Canadian family with compound heterozygote mutation H94Y/G145R. Both patients had presented with osteopetrosis, RTA, cerebral calcification and developmental delay, but cognitive impairment was absent. Further investigation revealed the complete absence of CA II activity in G145R mutant, but some residual activity was present in H94Y mutant. This residual activity might explain the absence of severe cognitive impairment [48].

CA II deficiency is recessive mixed proximal–distal (Type 3) RTA [52]. A predominance of the dRTA has been reported in some cases [53, 54]. The characteristic biochemical findings are bicarbonate wasting, inability to lower urine pH below 5.5, a low urine-to-blood pCO₂
difference in an alkaline urine and decreased NH₄ excretion [6].

An autosomal recessive syndrome of osteopetrosis, RTA and cerebral calcification was initially reported in 1972 [55, 56]. The cause was not known until in 1983 when CA II deficiency was identified as the main defect by Sly et al. [38]. Whyte et al. investigated three sisters who had presented with osteopetrosis in infancy [53]. Although osteopetrosis resolved spontaneously, during adolescence two of them developed basal ganglia calcification. Later RTA was diagnosed. Whyte et al. suggested that acidosis might have led to spontaneous resolution of osteopetrosis [53]. Hemolysates from the sisters, their unaffected siblings and parents were examined for CA II activity [38]. CA II activity was completely absent in the erythrocytes of the affected sisters, while it was half normal in parents.

In 2004, Shah et al. studied 20 families referred for CA II deficiency. All patients studied had osteopetrosis, RTA and developmental delay. Skeletal fractures were reported in an American, a Turkish and an Ecuadorian patient. Cerebral calcification was present in most of the patients. Other studies have reported facial dysmorphism with low set ears, hypertelorism and a depressed nasal bridge [57, 58]. There have been very few reports of nephrocalcinosis and renal stones [59]. A link between primary pulmonary hypertension and CA II deficiency has also been suggested [60]. Lotan et al. [60] reported the development of pulmonary hypertension in an affected member of an Arabic family carrying CA II mutation (H64SX). They hypothesized that as both conditions are rare, the probability of occurrence of both conditions by chance alone was unlikely.

Mild conductive hearing loss has been reported from Saudi Arabia [58, 61]. Middle ear effusion and ossicle ankylosis as a result of osteopetrosis was found to be the cause.

**Mechanism of dRTA in CA II deficiency**

Almost all bicarbonate filtered by the kidney is reabsorbed. Eighty percent of it is reabsorbed by the proximal tubules, 15% by the thick ascending limb and the rest by collecting tubules [47]. In the proximal tubule lumen, H₂CO₃ is catalyzed by membrane-anchored CA IV to H₂O and CO₂. Conversion to CO₂ facilitates reabsorption as HCO₃⁻ is relatively impermeable to the apical membrane of proximal tubule. In contrast, CO₂ freely diffuses across the apical membrane into the cytosol. In the cytosol, the CA II catalyzes the hydration of CO₂ to H⁺ and HCO₃⁻. HCO₃⁻ is transported across into the peritubular space by the sodium-bicarbonate cotransporter (NBCe1), while H⁺ reenters the tubular lumen via sodium-hydrogen exchanger (NHE3) forming H₂CO₃ with the filtered HCO₃⁻. CA II deficiency fails to regenerate H⁺ ion intracellularly, which is required for apical H⁺ secretion and thus bicarbonate reabsorption in the proximal tubule [47].

CA II deficiency also affects H⁺ secretion and HCO₃⁻ reabsorption in the distal nephron causing distal RTA. H⁺ is secreted by H⁺-ATPase in the tubular lumen, while bicarbonate is reabsorbed by sodium-bicarbonate AE1. The H⁺ ion and HCO₃⁻ are generated in the cytosol by the catalytic action of CA II on CO₂ and H₂O (Figure 1). Thus, CA II deficiency aside from bicarbonate wasting (proximal component) leads to inability to maximally acidify urine (distal component) [47]. A mixed pattern of proximal and distal RTA, therefore, ensues with cytosolic CA II deficiency.

Bone resorption occurs by osteoclasts through an acidification process in the extracellular bone resorptive lacunae [47, 62]. This is achieved by H⁺-ion secretion into the lacunae by H⁺-ATPase [62]. H⁺ is generated by the action of CA II, the only CA isoenzyme present in osteoclasts, through its action on H₂O and CO₂ in the cytosol of osteoclasts. This way CA II deficiency reduces bone resorption causing osteopetrosis, a consistent feature of CA II deficiency [47].

**V-ATPase gene mutations**

Vacuolar (H⁺)-ATPases are multisubunit enzymatic proton pumps with two domains: the cytoplasmic V1 domain and the transmembrane V0 domain [63, 64]. The cytoplasmic V1 domain hydrolyzes ATP while the transmembrane V0 translocates protons. The vacuolar (H⁺)-ATPase is an ATP-dependent proton pump that acidifies intracellular compartments or transports protons (H⁺) across the plasma membrane. It is found on the plasma membrane or in association with various intracellular organelles. The V1 domain is composed of eight types of subunits (A–H), whereas the V0 domain consists of six subunits (a, c, d, e and Ac45) [63]. V-ATPase subunits have a spatiotemporal gene expression pattern and are tissue and cell type specific [65]. V-ATPases have been identified in the plasma membranes of various cells, including renal intercalated cells, osteoclasts and macrophages [66]. The subunits reported to be involved in human diseases are the subunit B and subunit a of the V1 and V0 domain, respectively. Subunit a has four isoforms (a1–a4) and subunit B has two (B1 and B2) [66]. The isoforms that are present in a limited number of tissues such as the kidneys are B1 (ATP6V1B1), a4 (ATP6V0A4), G3, C2 and d2 [66]. Besides the kidney, B1 subunits are also present in epididymis, ciliary body of the eye and inner ear. The subunits a4 is present only in epididymis, inner ear and kidney. In the kidney, V-ATPases are localized in the apical membrane of Type A-intercalated cells and in the basolateral membrane of Type B-intercalated cells [66].

V-ATPases have remarkably diverse functions in different cells [63, 66]. Inside the cells, V-ATPases help in normal cell processes of receptor-mediated endocytosis, intracellular membrane trafficking, pro-hormone synthesis, protein degradation and neurotransmitter uptake [67]. They also facilitate cellular entry of various viruses and toxins. In the cellular plasma membrane, they help in renal H⁺ secretion, bone resorption and sperm maturation.

Mutations in specific subunits have been described to cause RTA, osteopetrosis and tumor metastasis [63, 68]. Mutations in ATP6V0A4 and ATP6V0B1 gene encoding a4 and B1 subunits have been linked to human inherited dRTA as discussed below [19, 69–71].
V-ATPase: ATP6V1B1 mutations

In 1999, Karet et al. [71] first studied the genetic basis of recessive dRTA in a subset of patients with associated sensorineural hearing loss (SNHL). Through genome-wide linkage analysis, they identified the locus of suspected mutations at chromosome 2p13 that was later identified as the ATP6V1B1 gene encoding B1 subunit. They studied 31 unrelated kindred with recessive dRTA. Twenty-seven of them had family history of consanguineous marriage. All reported cases were diagnosed at an early age with the majority diagnosed by age 1. Nineteen cases were identified with ATP6V1B1 mutation. A total of 87% of the cases had hearing impairment. Mean blood pH was 7.2; bicarbonate was 10.9 mmol/L and K⁺ was 3.1 mmol/L. Mean urinary pH was 7.3 consistent with inability to acidify urine. Since blood samples for genetic analysis for most of these patients were collected from all over the world, there was limited information on other tests of urinary acidification but the diagnosis of dRTA on clinical grounds seemed firm.

Joshua et al. [72] studied hearing loss in five children with dRTA from three unrelated families. All families had different ATP6V1B1 mutations. Hearing loss was diagnosed between 3 months and 2 years. Audiometric and imaging techniques were used to characterize the hearing loss. The hearing loss was bilateral, asymmetrical, progressive and sometimes had a conductive component. High resolution computed tomography, performed in four patients, showed as the only radiological abnormality, a bilaterally enlarged vestibular aqueduct [72].

Rotatory vertigo has also been described in dRTA. In 2010, Yashima et al. [73] reported a patient in whom renal calcification was found at the first month medical screening. Further investigation had led to the diagnosis of distal RTA. The patient had developed bilateral hearing loss by age 3 and had started using hearing aids. Since the age of 4, he had several attacks of rotating vertigo. Fluctuating hearing loss and vertigo were detected during the follow-up.

V-ATPase: ATP6V0A4 mutations

Karet et al. [70] studied a subset of recessive dRTA patients with normal hearing and identified a different locus of suspected mutation at chromosome 7q33–34. Through the positional cloning approach, the ATP6V0A1 gene encoding a4 subunit was identified at that locus [70]. Thirteen kindred with normal hearing were studied. All except one had a family history of consanguinity. All of them had presented in early childhood. All had severe metabolic acidosis and hypokalemia with normal renal function. Urinary pH was reported to be >6.5. All had nephrocalcinosis, and with the exception of two, they all had elevated urine calcium. Rickets was present in seven of them. Audiometric evaluation revealed normal hearing prompting the conclusion that the a4 gene mutations may not cause hearing impairment. Saito et al. [74] described a 2-month-old Japanese male infant who had presented with vomiting and failure to thrive. The patient had hyperchloremic metabolic acidosis, hypokalemia, a normal serum anion gap, a positive urine anion gap, nephrocalcinosis and high urine pH. Auditory brain stem response test also revealed normal hearing bilaterally.

Stover et al. [75] later described several novel mutations in the ATP6V0A4 gene causing autosomal recessive dRTA. The clinical and biochemical parameters were similar to those described earlier (Table 1). A follow-up of these patients, however, found hearing loss in some at a later age, including one at 33 years and another at 22 [75].

Urinary acidification is primarily controlled in the distal nephron. H⁺-ion secretion is coupled to bicarbonate absorption in the polarized Type A intercalated cells [69]. The V-ATPase present on the apical membrane of these cells are the main H⁺ ion secretory protein [69]. In response to a fall in the blood pH, ATP-powered V-ATPase can increase H⁺-ion secretion by several thousand fold. This secretion is coupled to bicarbonate absorption by the AE1 at the basolateral membrane of these cells (Figure 1). A defect in V-ATPase, therefore, disrupts the ability of the kidney to correct acidosis through acidifying urine [69, 70].

Immunoreactivity has localized B1 and a4 subunits at the apical membrane of Type A intercalated cells [66]. Several mutations causing dRTA have been located to the gene encoding these subunits. Premature termination codons, frameshift mutations and splice site mutations have been described in some, while in others missense mutations were identified.

V-ATPase gene mutations have been shown to display diminished pump activity in the setting of intact pump assembly [6, 76]. In their study of a4 subunit mutation R807Q and G820R, Su et al. [77] found that G820R mutation caused a complete loss of phosphofructokinase-1(PFK-1) binding to a4 subunit without affecting PFK-1 activity, whereas R807Q mutation reduced a4 subunit production rendering V-ATPase inactive. They also found that G820R resulted in the loss of proton transport by 78%, but caused only 36% loss in ATPase activity, which suggested the importance of a4/PFK-1 binding to couple the ATPase activity to proton transport [77]. A study on rat IMCD cells has revealed another possible mechanism, whereby the mutated subunit did

<table>
<thead>
<tr>
<th>Types of dRTA</th>
<th>Clinical features</th>
<th>Autosomal dominant (AE1)</th>
<th>Autosomal recessive (AE1)</th>
<th>V-ATPase mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of onset</td>
<td>Usually late</td>
<td>Usually early</td>
<td>Early</td>
<td>Severe</td>
</tr>
<tr>
<td>Severity of dRTA</td>
<td>Mild</td>
<td>Severe</td>
<td>Severe</td>
<td>Absent</td>
</tr>
<tr>
<td>Hemolytic anemia</td>
<td>Rare</td>
<td>Common</td>
<td>Common</td>
<td>Absent</td>
</tr>
<tr>
<td>Polycythaemia</td>
<td>Mild</td>
<td>Severe</td>
<td>Severe</td>
<td>Absent</td>
</tr>
<tr>
<td>Plasma bicarbonate</td>
<td>Near normal</td>
<td>Low</td>
<td>Low</td>
<td>Absent</td>
</tr>
<tr>
<td>Nephrocalcinosis</td>
<td>Usually late</td>
<td>Common</td>
<td>Common</td>
<td>Absent</td>
</tr>
<tr>
<td>Hearing loss</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
<td>Abnormal</td>
</tr>
<tr>
<td>Urinary pH</td>
<td>&gt;6.5</td>
<td>&gt;6.5</td>
<td>&gt;6.5</td>
<td>Abnormal</td>
</tr>
</tbody>
</table>
Mouse models of dRTA

In mouse models of genetic ablation of various acid–base transporters, the phenotypic features resemble some of the features of human hereditary distal RTA. Many of the features of patients with AE1 mutation are similar to AE1−/− mutant mice. These mice were noted to have stunted growth and hemolytic anemia with high mortality [80]. Stehberger et al. [81] reported that AE1−/− mice developed hyperchloremic metabolic acidosis and produced alkaline urine without bicarbonaturia. Furthermore, nephrocalcinosis, hypercalciumia, hyperphosphaturia and hypocitraturia were also noted. Immunochemistry and inhibited proton pump activity [78]. It has been suggested that this mechanism might be involved in B1 missense mutation R394Q wherein, unlike the usual autosomal recessive pattern of V-ATPase mutations, a dominant inheritance pattern was described and is extremely rare [6]. Interestingly, two patients were reported with dRTA and SNHL associated with mutations of ATP6V1B1 and ATP6V0A4 who both had medullary sponge kidney, a congenital disease characterized by diffuse ectasia or dilation of precalyceal collecting tubules [79]. The occurrence of dRTA in patients with medullary sponge kidney is generally felt to be an acquired defect in distal acidification that is usually mild. The possibility that a primary inherited defect in ATP6V1B1 and ATP6V0A4 in intercalated cells of the kidney may be involved in some cases deserved consideration based on the two cases reported by Carloni et al. [79].

Hearing loss and genetic screening considerations

Hearing loss is often seen in autosomal recessive dRTA. Based on the type of hearing loss, the type of mutations can be suspected. Conductive deafness is seen with CA II mutations, whereas SNHL is seen with ATP6V1B1 and ATP6V0A4 mutations. AE1 mutations, by contrast, usually do not have any associated deafness. This is a useful clinical distinguishing feature.

The kidney-specific a4 and B1 subunits of H+-ATPase have been identified in the inner ear as well. It is known that pH of endolymph plays an important role in hearing [85]. In the inner ear, endolymphatic pH is maintained by H+-ATPase and Cl−/HCO3− exchanger including pendrin. Disruption of their function, such as through mutations, lead to hearing loss [85]. Studies have reported that early SNHL (before the age of 10) occurs in most patients with ATP6V1B1 mutations, whereas late-onset SNHL is seen with ATP6V0A4 mutations [75, 86, 87]. There have been exceptions as noted by Vargas-Poussou et al. [88] who studied 39 families with autosomal recessive dRTA and identified V-ATPase mutations in 31 families. Twenty-one of them had ATP6V0A4 mutations, while only 10 had ATP6V1B1 mutations. In eight cases, these two mutations were not identified. Early-onset SNHL was observed in 70% of cases with ATP6V1B1 gene mutations and in 39% of cases with ATP6V0A4 gene mutations. Overall, 53.8% of the cases had ATP6V0A4 mutations and 25.6% of them had ATP6V1B1 mutations. Only 41% had hearing loss at the time of diagnosis. Based on these findings, Vargas-Poussou et al. [88] suggested that a genetic screening strategy based only on early or late-onset hearing loss would be misleading and proposed an algorithm for the genetic screening of autosomal recessive dRTA [88]. They suggested that the gene be investigated based on the presence or absence of consanguinity rather than hearing loss. In consanguineous families, homoygous mapping using microsatellite markers at the ATP6V1B1 and ATP6V0A4 loci could identify the mutations, and if inconclusive then ATP6V0A4 gene should be analyzed for mutation as it accounts for most cases of autosomal recessive dRTA [88]. For practical purposes, we think that sensorineural deafness is a useful feature for the clinician to suspect dRTA associated with ATP6V1B1 and ATP6V0A4 mutations. Although the presence of deafness and the type was suggested as an important clue to the genetic lesion underlying hereditary dRTA, it is now becoming more clear that this is only useful as an initial diagnostic impression. The findings that less than 50% of the hereditary RTA cases develop deafness and that most of them might develop deafness later on in life leaves genetic tests as the only definitive approach in identifying the defect accurately and early on in life. This is not to say, however, that deafness is not an important clue to the presence and the type of hereditary distal RTA. Faced with the presence of sensorineural
Diagnostic evaluation of distal RTA

The diagnosis of distal RTA should be suspected whenever a hyperchloremic metabolic acidosis is present without any obvious cause (i.e. diarrhea) in the setting of relatively normal GFR [2]. All that is usually needed for confirmation is an inappropriately low rate of acid excretion and information on urine pH. The urine pH is typically inappropriately high in the classic form (distal or Type 1 RTA), whereas it is low in Type 4 distal RTA (not discussed in this review).

Ammonium is the most important component of acid excretion in the presence of metabolic acidosis, and thus one has either to measure it directly or estimate it by calculating the urine anion gap [89]. In patients with a hyperchloremic acidosis, the urine anion gap is helpful in determining whether the acidosis is due to a renal or extrarenal etiology, with the caveats discussed below [89]. The principle is similar to that of the plasma anion gap, namely, that the sum of all cations and anions must be equal. Thus,

\[
\frac{[\text{Cl}^-] + [\text{HCO}_3^-] + \text{[unmeasured anions]}}{[\text{Na}^+] + [\text{K}^+] + \text{[unmeasured cations]}}
\]

The unmeasured anions include sulfate, phosphate and organic anions. Cations not routinely measured include NH$_4^+$, Ca$^{2+}$ and Mg$^{2+}$.

The urine anion gap will be low (usually a negative value) if there is a decrease in unmeasured anions or an increase in unmeasured cations (e.g. NH$_3$). The urine anion gap will be increased (usually a positive value) if there is an increase in unmeasured anions or a decrease in unmeasured cations. Because the concentrations of unmeasured anions in the urine do not change notably and because NH$_4^+$ is the major unmeasured cation in the presence of metabolic acidosis, the urine anion gap is a useful estimate of urine [NH$_4^+$] in this setting. Patients with an acidification defect typically have a positive gap (because NH$_4^+$ excretion is inappropriately low), whereas in diarrheal states (provided that distal Na$^+$ delivery is adequate) the gap is negative, reflecting the fact that NH$_4^+$ excretion is not impaired [89]. In proximal RTA, the urine anion gap is negative (provided plasma [HCO$_3^-$] is low) because distal acidification is normal.

Along with measurement of urine electrolytes and calculation of the anion gap, urine pH should be measured to assess the ability of the collecting duct to acidify the urine. Urine pH can be evaluated during spontaneous metabolic acidosis or after administration of an acidifying salt. It can also be assessed by the infusion of sodium sulfate or after giving furosemide (Figure 3). Therefore, provocative tests assess Na$^+$-dependent acidification and can provide additional useful mechanistic information [39, 90]. These agents increase distal Na$^+$ delivery, thereby enhancing the negative transepithelial potential in the collecting duct and stimulating H$^+$ and K$^+$ secretion. The role of furosemide can be more clearly exemplified by reversing its sodium delivery effect through the concomitant use of amiloride as shown in Figure 4. A reduction in urine pH and an increase in K$^+$ excretion after the administration of either of the above agents indicate a normal response to this enhanced electronegativity. It must be recognized, however, that the evidence obtained from these maneuvers is indirect and may be sometimes subject to different interpretations.

The theoretical features of urine acidification associated with the different types of transporter defects leading to
dRTA are shown in Figures 5 and 6. There is very limited information in this regard and, therefore, some of these features are theoretical.

Therapy of distal RTA

The aims of treatment of classic RTA are not only to correct the biochemical abnormalities, but also to improve growth in children, and to prevent kidney stones and the skeletal abnormalities associated with the disease. Another aim is to prevent the progression of nephrocalcinosis, which, in rare cases, leads to chronic renal failure. Alkali therapy should provide an adequate base to balance daily acid production.

Because children have a higher rate of acid production, they require higher doses of alkali. A mixture of sodium and potassium citrate salts is recommended. All patients with classic distal RTA have associated hypocitraturia, but children with this disorder also have calcium oxalate and calcium phosphate excretion rates that approach saturation, which makes them more susceptible to nephrolithiasis. Citrate salts correct the hypocitraturia and prevent nephrolithiasis [91]. This organic anion also corrects the metabolic acidosis, thereby decreasing urine calcium excretion. Infants require as much as 5–8 mEq per kg of citrate or HCO₃ per kg body weight, whereas adults require only about 0.5–1 mEq per kg body weight. Patients with hereditary distal RTA require lifetime treatment. The prognosis is excellent if the diagnosis is made early and appropriate amounts of alkali are continuously administered. However, alkali therapy has no effect on hearing impairment in those patients who have either sensorineural or conductive deafness [92]. Potassium supplementation is needed in the majority of patients with hypokalemic hereditary distal RTA. While systemic studies are not available, the use of amiloride 10 mg once a day, in our experience, is very useful to conserve potassium and, therefore, reduces the amount of potassium supplementation.

Fig. 5. Expected urine acidification features in the case of (A) the lack of function of kAE1 transporter and (B) mistargeting of kAE1 transporter to the apical membrane.
Conflict of interest statement. None declared.

References


Fig. 6. Expected urine acidification features in the case of (A) the lack of function of CA II in the \(\alpha\)-intercalated cells and (B) the lack of function of \(H^+\)-ATPase in the \(\alpha\)-intercalated cells.
42. Breton S. The cellular physiology of carbonic anhydrases. *JOP* 2001; 2: 159–164


Received for publication: 26.6.2012; Accepted in revised form: 14.8.2012